{"id":"idebenone","rwe":[{"pmid":"41878677","year":"2026","title":"Protective Effect of Idebenone Against UVB-Induced Photoaging in HaCaT Cells.","finding":"","journal":"Drug design, development and therapy","studyType":"Clinical Study"},{"pmid":"41822676","year":"2026","title":"Leber Hereditary Optic Neuropathy Caused by the Rare MT-ND1 m.3394T>C Mutation: A Case With Favorable Visual Prognosis and a Literature Review.","finding":"","journal":"Cureus","studyType":"Clinical Study"},{"pmid":"41707754","year":"2026","title":"Folic acid mitigation of alcohol-induced sarcopenia via gut-muscle axis modulation.","finding":"","journal":"Metabolism: clinical and experimental","studyType":"Clinical Study"},{"pmid":"41692294","year":"2026","title":"Neuroprotective effects of idebenone in a zebrafish model of Parkinson's disease via regulating autophagy, mitigating apoptosis and oxidative stress.","finding":"","journal":"Neuroscience","studyType":"Clinical Study"},{"pmid":"41547496","year":"2026","title":"Idebenone protects against doxorubicin-induced cardiac injury by inhibiting ferroptosis in cardiomyocytes.","finding":"","journal":"Experimental gerontology","studyType":"Clinical Study"}],"tags":[{"label":"idebenone","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Cytochrome P450 2C19","category":"target"},{"label":"CYP2C19","category":"gene"},{"label":"CYP2D6","category":"gene"},{"label":"CYP2C9","category":"gene"},{"label":"N06BX13","category":"atc"},{"label":"Active","category":"status"},{"label":"Leber's optic atrophy","category":"indication"},{"label":"Antioxidants","category":"pharmacology"},{"label":"Protective Agents","category":"pharmacology"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=IDEBENONE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:36:35.829095+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T00:03:22.971770+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:36:41.394775+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T01:36:35.901590+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=IDEBENONE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:36:41.623029+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL252556/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:36:42.327867+00:00"}},"allNames":"daruma","offLabel":[],"synonyms":["hydroxydecyl ubiquinone","CV-2619","CV 2619","idebenone","daruma","raxone"],"timeline":[{"date":"2015-09-08","type":"positive","source":"DrugCentral","milestone":"EMA approval"}],"aiSummary":"Idenbenone (Daruma) is a marketed drug primarily indicated for Leber's optic atrophy, leveraging its mechanism of increasing coenzyme Q10 levels to protect the optic nerve. A key strength of Daruma is its unique mechanism of action, which differentiates it from competitors such as abiraterone acetate, aliskiren, alprazolam, amiodarone, and amprenavir, all of which target different mechanisms despite some overlap. The primary risk for Daruma is the expiration of its key composition patent in 2028, which could lead to increased competition from generics.","approvals":[{"date":"2015-09-08","orphan":true,"company":"","regulator":"EMA"}],"brandName":"Daruma","ecosystem":[{"indication":"Leber's optic atrophy","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Cytochrome P450 2C19","targets":[{"gene":"CYP2C19","source":"DrugCentral","target":"Cytochrome P450 2C19","protein":"Cytochrome P450 2C19"},{"gene":"CYP2D6","source":"DrugCentral","target":"Cytochrome P450 2D6","protein":"Cytochrome P450 2D6"},{"gene":"CYP2C9","source":"DrugCentral","target":"Cytochrome P450 2C9","protein":"Cytochrome P450 2C9"},{"gene":"CYP3A4","source":"DrugCentral","target":"Cytochrome P450 3A4","protein":"Cytochrome P450 3A4"}],"modality":"Small Molecule","drugClass":"idebenone","explanation":"","oneSentence":"","technicalDetail":"Idebenone is a synthetic analogue of coenzyme Q10 that acts as a potent antioxidant and electron carrier, increasing the levels of reduced coenzyme Q10 in cells and thereby reducing oxidative stress and mitochondrial dysfunction."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1416","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=IDEBENONE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=IDEBENONE","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T11:59:57.705692","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:36:43.976174+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"abiraterone acetate","drugSlug":"abiraterone-acetate","fdaApproval":"2011-04-28","patentExpiry":"May 20, 2034","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"aliskiren","drugSlug":"aliskiren","fdaApproval":"2007-03-05","patentExpiry":"Feb 19, 2026","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"alprazolam","drugSlug":"alprazolam","fdaApproval":"1981-10-16","genericCount":24,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"amiodarone","drugSlug":"amiodarone","fdaApproval":"1985-12-24","patentExpiry":"Mar 13, 2029","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"amprenavir","drugSlug":"amprenavir","fdaApproval":"1999-04-15","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"aprepitant","drugSlug":"aprepitant","fdaApproval":"2003-03-27","patentExpiry":"Sep 26, 2027","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"astemizole","drugSlug":"astemizole","fdaApproval":"1988-12-31","relationship":"same-target"},{"drugName":"atazanavir","drugSlug":"atazanavir","fdaApproval":"2003-06-20","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"atorvastatin","drugSlug":"atorvastatin","fdaApproval":"1996-12-17","patentExpiry":"Jun 7, 2037","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"bromocriptine","drugSlug":"bromocriptine","fdaApproval":"1978-06-28","patentExpiry":"Jun 7, 2030","patentStatus":"Patent protected","relationship":"same-target"}],"genericName":"idebenone","indications":{"approved":[{"name":"Leber's optic atrophy","source":"DrugCentral","snomedId":58610003,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"abiraterone-acetate","brandName":"abiraterone acetate","genericName":"abiraterone acetate","approvalYear":"2011","relationship":"same-target"},{"drugId":"aliskiren","brandName":"aliskiren","genericName":"aliskiren","approvalYear":"2007","relationship":"same-target"},{"drugId":"alprazolam","brandName":"alprazolam","genericName":"alprazolam","approvalYear":"1981","relationship":"same-target"},{"drugId":"amiodarone","brandName":"amiodarone","genericName":"amiodarone","approvalYear":"1985","relationship":"same-target"},{"drugId":"amprenavir","brandName":"amprenavir","genericName":"amprenavir","approvalYear":"1999","relationship":"same-target"},{"drugId":"aprepitant","brandName":"aprepitant","genericName":"aprepitant","approvalYear":"2003","relationship":"same-target"},{"drugId":"astemizole","brandName":"astemizole","genericName":"astemizole","approvalYear":"1988","relationship":"same-target"},{"drugId":"atazanavir","brandName":"atazanavir","genericName":"atazanavir","approvalYear":"2003","relationship":"same-target"},{"drugId":"atorvastatin","brandName":"atorvastatin","genericName":"atorvastatin","approvalYear":"1996","relationship":"same-target"},{"drugId":"bromocriptine","brandName":"bromocriptine","genericName":"bromocriptine","approvalYear":"1978","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT04669158","phase":"PHASE1,PHASE2","title":"Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis","status":"COMPLETED","sponsor":"Stanford University","startDate":"2021-07-30","conditions":["Non Alcoholic Steatohepatitis","Fibrosis"],"enrollment":53,"completionDate":"2023-07-05"},{"nctId":"NCT01568658","phase":"","title":"Genetic and Physical Study of Childhood Nerve and Muscle Disorders","status":"RECRUITING","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2012-03-20","conditions":["Muscular Dystrophies","Muscle Myopathies","Hereditary Spastic Paraplegias","Inherited Neuropathies","Inherited Neuromuscular Conditions"],"enrollment":9300,"completionDate":""},{"nctId":"NCT04534023","phase":"PHASE2","title":"A Clinical Study of the Efficacy of Idebenone in the Treatment of iRBD Into Synucleinopathies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2020-08-31","conditions":["Rapid Eye Movement Sleep Behavior Disorder","Synucleinopathy"],"enrollment":28,"completionDate":"2026-11-30"},{"nctId":"NCT06429059","phase":"PHASE2","title":"ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) To Personalize Treatments","status":"COMPLETED","sponsor":"Duke University","startDate":"2024-06-12","conditions":["Amyotrophic Lateral Sclerosis ALS"],"enrollment":50,"completionDate":"2025-06-24"},{"nctId":"NCT04151472","phase":"PHASE3","title":"Idebenone for the Preventive Treatment of Migraine","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-12-08","conditions":["Migraine Disorders","Headache Disorders"],"enrollment":180,"completionDate":"2025-12-31"},{"nctId":"NCT04152655","phase":"PHASE2,PHASE3","title":"A Study of Efficacy and Safety of Idebenone Vs. Placebo in Prodromal Parkinson Disease","status":"WITHDRAWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-01-01","conditions":["REM Sleep Behavior Disorder","Parkinson Disease"],"enrollment":0,"completionDate":"2023-01-01"},{"nctId":"NCT05987397","phase":"PHASE4","title":"Exploring the Preventive Effect of Mitochondrial Protective Agent Idebenone on Post-stroke Epilepsy","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2023-07-05","conditions":["Post Stroke Epilepsy"],"enrollment":2700,"completionDate":"2025-12-31"},{"nctId":"NCT00537680","phase":"PHASE3","title":"Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia","status":"COMPLETED","sponsor":"Santhera Pharmaceuticals","startDate":"2007-12","conditions":["Friedreich's Ataxia"],"enrollment":70,"completionDate":"2009-04"},{"nctId":"NCT00697073","phase":"PHASE3","title":"Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients","status":"COMPLETED","sponsor":"Santhera Pharmaceuticals","startDate":"2008-07","conditions":["Friedreich's Ataxia"],"enrollment":68,"completionDate":"2010-05"},{"nctId":"NCT05931029","phase":"","title":"Study of the Therapeutic Effects of Naohuan Dan and Idebenone in Treating Mild Cognitive Impairment With Kidney Deficiency and Phlegm Stasis","status":"COMPLETED","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2019-05-01","conditions":["Mild Cognitive Impairment"],"enrollment":64,"completionDate":"2022-04-30"},{"nctId":"NCT03433807","phase":"","title":"Expanded Access Program for Idebenone in Participants With Duchenne Muscular Dystrophy (DMD)","status":"NO_LONGER_AVAILABLE","sponsor":"Santhera Pharmaceuticals","startDate":"","conditions":["Duchenne Muscular Dystrophy"],"enrollment":0,"completionDate":""},{"nctId":"NCT02774005","phase":"PHASE4","title":"Study to Assess the Efficacy and Safety of Raxone in LHON Patients","status":"COMPLETED","sponsor":"Santhera Pharmaceuticals","startDate":"2016-05","conditions":["Leber's Hereditary Optic Neuropathy (LHON)"],"enrollment":199,"completionDate":"2021-03-29"},{"nctId":"NCT04381091","phase":"","title":"Expanded Access Program for Idebenone in Patients With Leber's Hereditary Optic Neuropathy Who Completed the LEROS Study","status":"NO_LONGER_AVAILABLE","sponsor":"Santhera Pharmaceuticals","startDate":"","conditions":["Leber's Hereditary Optic Neuropathy"],"enrollment":0,"completionDate":""},{"nctId":"NCT05411978","phase":"PHASE4","title":"Safety and Efficacy of Oral Idebenone for Preventive Treatment of Migraine in Adult Migraine Patients","status":"UNKNOWN","sponsor":"Beijing Tiantan Hospital","startDate":"2022-05-09","conditions":["Migraine"],"enrollment":900,"completionDate":"2024-06-20"},{"nctId":"NCT03603288","phase":"PHASE3","title":"Phase III Study With Idebenone in Patients With Duchenne Muscular Dystrophy (SIDEROS-E)","status":"TERMINATED","sponsor":"Santhera Pharmaceuticals","startDate":"2018-07-04","conditions":["Duchenne Muscular Dystrophy"],"enrollment":161,"completionDate":"2020-11-25"},{"nctId":"NCT02814019","phase":"PHASE3","title":"A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocorticoid Steroids","status":"TERMINATED","sponsor":"Santhera Pharmaceuticals","startDate":"2016-09","conditions":["Duchenne Muscular Dystrophy (DMD)"],"enrollment":255,"completionDate":"2020-12-01"},{"nctId":"NCT02771379","phase":"","title":"Post Authorisation Safety Study With Raxone in LHON Patients","status":"COMPLETED","sponsor":"Santhera Pharmaceuticals","startDate":"2016-09","conditions":["Leber's Hereditary Optic Neuropathy (LHON)"],"enrollment":229,"completionDate":"2021-04-16"},{"nctId":"NCT01854359","phase":"PHASE1,PHASE2","title":"Idebenone for Primary Progressive Multiple Sclerosis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-03-12","conditions":["Multiple Sclerosis","Primary Progressive Multiple Sclerosis"],"enrollment":61,"completionDate":"2018-10-31"},{"nctId":"NCT04071639","phase":"PHASE1","title":"Symptomatic Therapy for Patients With Huntington's Disease","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-03-12","conditions":["Huntington Disease"],"enrollment":60,"completionDate":"2024-12-31"},{"nctId":"NCT00950248","phase":"PHASE1,PHASE2","title":"Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-11-01","conditions":["Primary Progressive Multiple Sclerosis"],"enrollment":85,"completionDate":"2018-08-06"},{"nctId":"NCT00229632","phase":"PHASE2","title":"Idebenone to Treat Friedreich's Ataxia","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2005-09-27","conditions":["Friedreich Ataxia"],"enrollment":51,"completionDate":"2007-12-17"},{"nctId":"NCT03727295","phase":"PHASE4","title":"Idebenone Treatment of Early Parkinson's Diseasesymptoms","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2019-01-01","conditions":["Oxidative Stress is an Important Cause of Parkinson's Disease"],"enrollment":180,"completionDate":"2021-05-30"},{"nctId":"NCT00993967","phase":"PHASE3","title":"Long-Term Safety and Tolerability of Idebenone in Friedreich's Ataxia Patients (MICONOS Extension)","status":"COMPLETED","sponsor":"Santhera Pharmaceuticals","startDate":"2007-06","conditions":["Freidreich's Ataxia"],"enrollment":200,"completionDate":"2012-06"},{"nctId":"NCT02887443","phase":"PHASE1","title":"A Study to Assess the Potential for Pre-systemic Inhibition of CYP3A by Idebenone Using Midazolam as a Substrate","status":"COMPLETED","sponsor":"Santhera Pharmaceuticals","startDate":"2016-09","conditions":["Drug-Drug Interaction"],"enrollment":32,"completionDate":"2016-11"},{"nctId":"NCT00887562","phase":"PHASE2","title":"Study of Idebenone in the Treatment of Mitochondrial Encephalopathy Lactic Acidosis & Stroke-like Episodes","status":"COMPLETED","sponsor":"Michio Hirano","startDate":"2009-05","conditions":["MELAS Syndrome"],"enrollment":27,"completionDate":"2012-07"},{"nctId":"NCT00905268","phase":"PHASE3","title":"A Study of Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia (FRDA) Patients","status":"COMPLETED","sponsor":"Santhera Pharmaceuticals","startDate":"2006-04","conditions":["Friedreich's Ataxia"],"enrollment":232,"completionDate":"2010-01"},{"nctId":"NCT01303406","phase":"PHASE3","title":"Patient Reported Outcomes in Friedreich's Ataxia Patients After Withdrawal From Treatment With Idebenone (PROTI)","status":"COMPLETED","sponsor":"Santhera Pharmaceuticals","startDate":"2011-04","conditions":["Friedreich's Ataxia"],"enrollment":29,"completionDate":"2012-07"},{"nctId":"NCT01027884","phase":"PHASE3","title":"Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD)","status":"COMPLETED","sponsor":"Santhera Pharmaceuticals","startDate":"2009-07","conditions":["Muscular Dystrophy, Duchenne","Ambulatory Care"],"enrollment":65,"completionDate":"2014-04"},{"nctId":"NCT01495715","phase":"PHASE3","title":"Study With Idebenone in Patients With Chronic Vision Loss Due to Leber's Hereditary Optic Neuropathy (LHON)","status":"WITHDRAWN","sponsor":"Santhera Pharmaceuticals","startDate":"","conditions":["Leber's Hereditary Optic Neuropathy"],"enrollment":0,"completionDate":""},{"nctId":"NCT00747487","phase":"PHASE2","title":"Study to Assess Efficacy,Safety and Tolerability of Idebenone in the Treatment of Leber's Hereditary Optic Neuropathy","status":"COMPLETED","sponsor":"Santhera Pharmaceuticals","startDate":"2007-11","conditions":["Leber's Hereditary Optic Neuropathy"],"enrollment":85,"completionDate":"2010-02"},{"nctId":"NCT01421381","phase":"","title":"RHODOS Follow-up Single-visit Study","status":"COMPLETED","sponsor":"Santhera Pharmaceuticals","startDate":"2011-09","conditions":["Leber's Hereditary Optic Neuropathy"],"enrollment":60,"completionDate":"2011-12"},{"nctId":"NCT00654784","phase":"PHASE2","title":"Efficacy and Tolerability of Idebenone in Boys With Cardiac Dysfunction Associated With Duchenne Muscular Dystrophy","status":"COMPLETED","sponsor":"Santhera Pharmaceuticals","startDate":"2005-10","conditions":["Duchenne Muscular Dystrophy (DMD)"],"enrollment":21,"completionDate":"2007-08"},{"nctId":"NCT00758225","phase":"PHASE2","title":"Long-term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension)","status":"COMPLETED","sponsor":"Santhera Pharmaceuticals","startDate":"2008-09","conditions":["Duchenne Muscular Dystrophy"],"enrollment":21,"completionDate":"2011-01"},{"nctId":"NCT00078481","phase":"PHASE1","title":"Phase 1 Trial of Idebenone to Treat Patients With Friedreich's Ataxia","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2004-02","conditions":["Friedreich Ataxia"],"enrollment":16,"completionDate":"2006-04"},{"nctId":"NCT00015808","phase":"PHASE1","title":"Safety Study of Idebenone to Treat Friedreich's Ataxia","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2001-05","conditions":["Friedreich Ataxia"],"enrollment":100,"completionDate":"2006-04"}],"_emaApprovals":[{"date":"2015-09-08","status":"Authorised","company":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"006795","UNII":"HB6PN45W4J","CHEBI":"CHEBI:31687","INN_ID":"5465","RXNORM":"51296","UMLSCUI":"C0123163","chemblId":"CHEMBL252556","ChEMBL_ID":"CHEMBL252556","KEGG_DRUG":"D01750","DRUGBANK_ID":"DB09081","PUBCHEM_CID":"3686","SNOMEDCT_US":"428158006","MESH_SUPPLEMENTAL_RECORD_UI":"C036619"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":788,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"N06BX13","allCodes":["N06BX13"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026","pmid":"41878677","title":"Protective Effect of Idebenone Against UVB-Induced Photoaging in HaCaT Cells.","journal":"Drug design, development and therapy"},{"date":"2026 Feb","pmid":"41822676","title":"Leber Hereditary Optic Neuropathy Caused by the Rare MT-ND1 m.3394T>C Mutation: A Case With Favorable Visual Prognosis and a Literature Review.","journal":"Cureus"},{"date":"2026 May","pmid":"41707754","title":"Folic acid mitigation of alcohol-induced sarcopenia via gut-muscle axis modulation.","journal":"Metabolism: clinical and experimental"},{"date":"2026 Apr 6","pmid":"41692294","title":"Neuroprotective effects of idebenone in a zebrafish model of Parkinson's disease via regulating autophagy, mitigating apoptosis and oxidative stress.","journal":"Neuroscience"},{"date":"2026 Feb","pmid":"41547496","title":"Idebenone protects against doxorubicin-induced cardiac injury by inhibiting ferroptosis in cardiomyocytes.","journal":"Experimental gerontology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"2015","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:36:43.976174+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}